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patients	 with	 a	 first	 diagnosis	 between	 2004	 and	 2013	 with	 an	 adjuvant	 chemotherapy	
pathway	(n=738).	This	produced	an	event	log	data	file	(containing	events,	dates	and	times)	
which	was	analysed	using	the	ProM	process	mining	tool	(www.promtools.org).	We	used	the	




Most	 patients	 varied	 from	 the	 expected	 pathway	 (712	 variants	 for	 738	 patients).	 We	
produced	a	pathway	model	which	included	these	variants	and	checked	conformance.	Overall	
fitness	of	data	to	model	was	high	(97.1%)	but	we	noted	significant	changes	to	the	fit	in	2006	
(a	5.1%	change)	and	2011	 (8.9%	change)	which	 require	 further	 investigation.	 In	 total	51%	
(n=376)	of	patients	did	complete	all	six	cycles,	less	than	half	(21%	of	total,	n=158)	completed	
the	 cycles	 without	 an	 adverse	 event	 while	 many	 (30%,	 n=218)	 experienced	 at	 least	 one	




Process	mining	 of	 routine	 data	 showed	 extensive	 variation	 from	 standard	 chemotherapy	
pathways	 including	 incomplete	 treatment	 and	 adverse	 events.	 Future	 work	 is	 needed	 to	
explore	potential	causal	links	and	understand	changes	in	the	pathway	over	time.		
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